Intersect ENT Inc (XENT) Holdings Boosted by Pura Vida Investments LLC
Pura Vida Investments LLC raised its position in shares of Intersect ENT Inc (NASDAQ:XENT) by 122.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 190,335 shares of the medical equipment provider’s stock after purchasing an additional 104,808 shares during the quarter. Intersect ENT comprises 3.3% of Pura Vida Investments LLC’s portfolio, making the stock its 9th largest holding. Pura Vida Investments LLC owned about 0.62% of Intersect ENT worth $5,364,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. NumerixS Investment Technologies Inc boosted its stake in Intersect ENT by 43.0% during the 4th quarter. NumerixS Investment Technologies Inc now owns 2,200 shares of the medical equipment provider’s stock valued at $60,000 after purchasing an additional 662 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Intersect ENT by 183.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,617 shares of the medical equipment provider’s stock worth $74,000 after acquiring an additional 1,694 shares in the last quarter. Meeder Asset Management Inc. boosted its stake in shares of Intersect ENT by 215.0% during the 4th quarter. Meeder Asset Management Inc. now owns 5,604 shares of the medical equipment provider’s stock worth $159,000 after acquiring an additional 3,825 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Intersect ENT by 15.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,194 shares of the medical equipment provider’s stock worth $230,000 after acquiring an additional 1,114 shares in the last quarter. Finally, Tekla Capital Management LLC bought a new stake in shares of Intersect ENT during the 3rd quarter worth $240,000.
Several equities research analysts have recently weighed in on the company. ValuEngine raised Intersect ENT from a “hold” rating to a “buy” rating in a research note on Saturday, February 23rd. Zacks Investment Research lowered Intersect ENT from a “buy” rating to a “hold” rating in a research note on Sunday, January 6th. Canaccord Genuity raised their price objective on Intersect ENT from $36.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, February 26th. BTIG Research reissued a “hold” rating on shares of Intersect ENT in a research note on Tuesday, February 26th. Finally, BidaskClub raised Intersect ENT from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 1st. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $37.40.
Intersect ENT (NASDAQ:XENT) last released its quarterly earnings data on Monday, February 25th. The medical equipment provider reported ($0.16) earnings per share for the quarter, hitting the consensus estimate of ($0.16). The business had revenue of $32.80 million during the quarter, compared to analyst estimates of $32.68 million. Intersect ENT had a negative return on equity of 19.04% and a negative net margin of 21.13%. The company’s revenue was up 11.2% compared to the same quarter last year. During the same period last year, the company posted ($0.11) EPS. On average, research analysts anticipate that Intersect ENT Inc will post -0.95 earnings per share for the current year.
In other news, insider Lisa D. Earnhardt sold 20,000 shares of the firm’s stock in a transaction on Monday, December 17th. The stock was sold at an average price of $29.73, for a total value of $594,600.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 5.90% of the company’s stock.
About Intersect ENT
Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.
Featured Article: The mechanics of the bid-ask spread in trading
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.